<ENAMEX TYPE="ORGANIZATION">Quadra Logic Technologies Inc.</ENAMEX> said it plans to issue three million new common shares, $5 million of which will be sold to its 15.2%-owner, <ENAMEX TYPE="ORGANIZATION">American Cyanamid Co.</ENAMEX>
Terms of the offering, which is expected by late October, weren't disclosed. In national over-the-counter trading, <ENAMEX TYPE="ORGANIZATION">Quadra Logic</ENAMEX> closed at $7.50 a share, down 75 cents, giving the planned share issue a current market value of about $22.5 million. A <ENAMEX TYPE="ORGANIZATION">Quadra Logic</ENAMEX> official said <ENAMEX TYPE="ORGANIZATION">American Cyanamid</ENAMEX>'s stake in the company wouldn't be affected by the offering.
In a related announcement, <ENAMEX TYPE="ORGANIZATION">Quadra Logic</ENAMEX>, a biopharmaceutical concern that is developing an anti-cancer drug, <ENAMEX TYPE="LOCATION">Photofrin</ENAMEX>, said it expects to receive as much as $8 million from <ENAMEX TYPE="ORGANIZATION">American Cyanamid</ENAMEX> for marketing and distribution rights to products being developed to treat venereal warts and psoriasis. The accord, which requires board approvals, provides, among other things, for <ENAMEX TYPE="ORGANIZATION">American Cyanamid</ENAMEX> to co-develop the products.
<ENAMEX TYPE="ORGANIZATION">Quadra Logic</ENAMEX> said <ENAMEX TYPE="ORGANIZATION">American Cyanamid</ENAMEX> also agreed to provide a secured loan of as much as $10 million to help finance further development of <ENAMEX TYPE="ORGANIZATION">Photofrin</ENAMEX>, a light-activated compound that generates toxic chemicals that kill cancer cells. <ENAMEX TYPE="ORGANIZATION">Quadra Logic</ENAMEX> is currently seeking Canadian regulatory approval to sell the drug in <ENAMEX TYPE="LOCATION">Canada</ENAMEX>.
